More than half of all US adults are eligible for semaglutide therapy

Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and cardiovascular disease prevention.

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Study results 18.10.2023 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz

October 19, 2023

PROs Support Practice-Changing RUBY Trial in Endometrial Cancer

The buzz created by two phase III studies testing immunotherapy in advanced or recurrent endometrial cancer at the Society of Gynecologic Oncology (SGO) annual meeting

June 21, 2023

TULSA Effective in Controlling Prostate Cancer Long-Term

WASHINGTON — Results from a long-term follow-up of the pivotal TACT trial showed that MRI-guided transurethral ultrasound ablation (TULSA) was effective and durable in men

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.